SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Wells G, Beaton D, Shea B, Boers M, Simon L, Strand V, et al. Minimal clinically important differences: review of methods [review]. J Rheumatol 2001; 28: 40612.
  • 2
    Kirwan JR. Minimum clinically important difference: the crock of gold at the end of the rainbow? J Rheumatol 2001; 28: 43944.
  • 3
    Jaeschke R, Singer J, Guyatt GH. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10: 40715.
  • 4
    Wells GA, Boers M, Shea B, Brooks PM, Simon LS, Strand CV, et al. Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol 2005; 32: 201624.
  • 5
    Tubach F, Ravaud P, Baron G, Logeart I, Bellamy N, Bombardier, et al. Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state. Ann Rheum Dis 2005; 64: 347.
  • 6
    Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993; 20: 55760.
  • 7
    Tubach F, Wells GA, Ravaud P, Dougados M. Minimal clinically important difference, low disease activity state, and patient acceptable symptom state: methodological issues. J Rheumatol 2005; 32: 20259.
  • 8
    Tubach F, Pham T, Skomsvoll J, Mikkelsen K, Bjorneboe O, Ravaud P, et al. Determination of the patient acceptable symptom state in outcome criteria in ankylosing spondylitis [abstract]. Ann Rheum Dis 2005; 64 Suppl 3: 97.
  • 9
    Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 3618.
  • 10
    Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21: 22815.
  • 11
    Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 228691.
  • 12
    Jones SD, Steiner A, Garrett SL, Calin A. The Bath Ankylosing Spondylitis patient Global score (BAS-G). Br J Rheumatol 1996; 35: 6671.
  • 13
    Doward LC, Spoorenberg A, Cook SA, Whalley D, Helliwell PS, Kay LJ, et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 2003; 62: 206.
  • 14
    Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing Spondylitis Assessment Group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001; 44: 187686.
  • 15
    Van der Heijde DM, van der Linden S. Measures of outcome in ankylosing spondylitis and other spondyloarthritides. Baillieres Clin Rheumatol 1998; 12: 68393.
  • 16
    Lorraine PJ, Hammock RL, Blanton JM. Predictors of self-rated health status among Texas residents. Prev Chronic Dis 2005; 2: A12.
  • 17
    Van Manen JG, Bindels PJ, Dekker EW, Ijzermans CJ, Bottema BJ, van der Zee JS, et al. Added value of co-morbidity in predicting health-related quality of life in COPD patients. Respiratory Med 2001; 95: 496504.
  • 18
    Boonen A. Socioeconomic consequences of ankylosing spondylitis [review]. Clin Exp Rheumatol 2002; 20 Suppl 28: S236.
  • 19
    Goldstein LH, Holland L, Soteriou H, Mellers JD. Illness representations, coping styles and mood in adults with epilepsy. Epilepsy Res 2005; 67: 111.
  • 20
    Krell HV, Leuchter AF, Morgan M, Cook IA, Abrams M. Subject expectations of treatment effectiveness and outcome of treatment with an experimental antidepressant. J Clin Psych 2004; 65: 11749.
  • 21
    Gunther V, Mur E, Traweger C, Hawel R. Stress coping of patients with ankylosing spondylitis. J Psychosom Res 1994; 38: 41927.
  • 22
    Cieza A, Stucki G. Understanding functioning, disability, and health in rheumatoid arthritis: the basis for rehabilitation care. Curr Opin Rheumatol 2005; 17: 1839.
  • 23
    Cohen JD, Cunin P, Farrenq V, Oniankitan O, Carton L, Chevalier X, et al. Estimation of the Bath Ankylosing Spondylitis Disease Activity Index cutoff for perceived symptom relief in patients with spondyloarthropathies. J Rheumatol 2006; 33: 7981.
  • 24
    Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet 2002; 359: 118793.
  • 25
    Van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al, and the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized placebo-controlled trial (ASSERT). Arthritis Rheum 2005; 52: 58291.
  • 26
    Braun J, Pham T, Sieper J, van der Linden S, Dougados M, van der Heijde D, and the ASAS Working Group. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003; 62: 81724.